These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 2881923

  • 21. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T, Marder SR, Mintz J.
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [Abstract] [Full Text] [Related]

  • 22. Neuroleptic bioavailability, psychosocial factors, and clinical status: a 1-year study of schizophrenic outpatients after dose reduction.
    Faraone SV, Curran JP, Laughren T, Faltus F, Johnston R, Brown WA.
    Psychiatry Res; 1986 Dec; 19(4):311-22. PubMed ID: 2880360
    [Abstract] [Full Text] [Related]

  • 23. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G, Coyle J, Tune L.
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [Abstract] [Full Text] [Related]

  • 24. Neuroleptic nonresponse and affective symptoms: a 2-year prospective study of schizophrenic outpatients.
    Faraone SV, Young AS, Brown WA.
    Psychiatry Res; 1989 Jun; 28(3):315-21. PubMed ID: 2569751
    [Abstract] [Full Text] [Related]

  • 25. Treating prodromal episodes to prevent relapse in schizophrenia.
    Herz MI, Glazer W, Mirza M, Mostert M, Hafez H.
    Br J Psychiatry Suppl; 1989 Jul; (5):123-7. PubMed ID: 2574984
    [No Abstract] [Full Text] [Related]

  • 26. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
    Pecknold JC.
    J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
    [Abstract] [Full Text] [Related]

  • 27. Sociodemographic and clinical factors associated with relapse in schizophrenia.
    Chabungbam G, Avasthi A, Sharan P.
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):587-93. PubMed ID: 18081617
    [Abstract] [Full Text] [Related]

  • 28. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients.
    Zohar J, Kaplan Z, Benjamin J.
    J Clin Psychiatry; 1993 Oct; 54(10):385-8. PubMed ID: 7903293
    [Abstract] [Full Text] [Related]

  • 29. [The effect of propranolol, neuroleptics and their combination on serum prolactin levels of schizophrenic patients].
    Elizur A, Segal Z, Yeret A, Aboo-Shach M, Ben-David M.
    Harefuah; 1979 Sep; 97(5-6):101-4. PubMed ID: 44254
    [No Abstract] [Full Text] [Related]

  • 30. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
    Linden M, Scheel T, Eich FX.
    J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
    [Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M.
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [Abstract] [Full Text] [Related]

  • 32. Alterations in DHEA metabolism in schizophrenia: two-month case-control study.
    Ritsner M, Gibel A, Ram E, Maayan R, Weizman A.
    Eur Neuropsychopharmacol; 2006 Feb; 16(2):137-46. PubMed ID: 16139994
    [Abstract] [Full Text] [Related]

  • 33. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA, Milanes F, Starkey T, Slater V, Dominguez F.
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract] [Full Text] [Related]

  • 34. Relation of serum molindone levels to serum prolactin levels and antipsychotic response.
    Pandurangi AK, Narasimhachari N, Blackard WG, Landa BS.
    J Clin Psychiatry; 1989 Oct; 50(10):379-81. PubMed ID: 2676994
    [Abstract] [Full Text] [Related]

  • 35. [Detection of early warning signs in schizophrenic patients. Possible applications in prevention of recurrence].
    Wiedemann G, Hahlweg K, Hank G, Feinstein E, Müller U, Dose M.
    Nervenarzt; 1994 Jul; 65(7):438-43. PubMed ID: 7800087
    [Abstract] [Full Text] [Related]

  • 36. A preliminary dose-ranging trial of proglumide for the treatment of refractory schizophrenics.
    Hicks PB, Vinogradov S, Riney SJ, Su K, Csernansky JG.
    J Clin Psychopharmacol; 1989 Jun; 9(3):209-12. PubMed ID: 2567742
    [Abstract] [Full Text] [Related]

  • 37. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?
    Gaebel W, Frick U, Köpcke W, Linden M, Müller P, Müller-Spahn F, Pietzcker A, Tegeler J.
    Br J Psychiatry Suppl; 1993 Sep; (21):8-12. PubMed ID: 8105814
    [Abstract] [Full Text] [Related]

  • 38. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects.
    Taira M, Hashimoto T, Takamatsu T, Maeda K.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug 30; 30(6):1139-42. PubMed ID: 16765499
    [Abstract] [Full Text] [Related]

  • 39. Prodromal symptoms and prevention of relapse in schizophrenia.
    Herz M.
    J Clin Psychiatry; 1985 Nov 30; 46(11 Pt 2):22-5. PubMed ID: 2865253
    [Abstract] [Full Text] [Related]

  • 40. Low serum neuroleptic levels predict relapse in schizophrenic patients.
    Brown WA, Laughren T, Chisholm E, Williams BW.
    Arch Gen Psychiatry; 1982 Sep 30; 39(9):998-1000. PubMed ID: 6126172
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.